

#### TEXAS STATE BOARD OF PHARMACY

## 1601 Congress Ave, Room 2.034 Austin, Texas

Tuesday, November 7, 2023

#### MINUTES1

#### **BOARD BUSINESS MEETING**

#### Tuesday, November 7, 2023

President Julie Spier, R.Ph., called the meeting to order at 9:01 a.m. Other Board Members present were Vice President Donnie Lewis, R.Ph.; Treasurer Rick Fernandez, R.Ph.; Daniel Guerrero; Lori Henke, Pharm.D.; Bradley A. Miller, Ph.T.R.; Donna Montemayor, R.Ph.; Suzette Tijerina, R.Ph.; Rick Tisch; and Jenny Downing Yoakum, R.Ph.

Board Member Ian Shaw was not in attendance.

Staff present were Daniel Carroll, Pharm.D., R.Ph., Executive Director/Secretary; Megan Holloway, General Counsel; Caroline Hotchkiss, Director of Enforcement; John Griffith, Litigation Counsel; Ann Driscoll, Ph.T.R., Director of Operations; Ruben Leal, Budget Analyst; Eamon Briggs, Deputy General Counsel; Sean Leeper, Government Relations Specialist; Misty Anderson, Director of Licensing; Shayda Bakhshi, Outreach Coordinator; and Lily Moreno, Executive Assistant.

#### A. Announcements

President Spier welcomed Dr. Carroll in the position of Executive Director/Secretary and reviewed Dr. Carroll's background. Ms. Holloway reported the promotion of David Meryman, in his new role as Prescription Monitoring Program Manager, and introduced new Board staff member Sean Leeper, Government Relations Specialist.

President Spier made general announcements, including concerning continuing education credit for attending the Board Meeting, and reviewed the meeting procedures.

<sup>&</sup>lt;sup>1</sup>See agenda and corresponding attachments for supporting materials.

## B. <u>Discussion and Approval of Minutes of Previous Meetings</u> (Item B)

Following discussion, the motion was made by Mr. Guerrero to approve the minutes of the Board Business Meeting held August 1, 2023, and the minutes of the Board Business Meeting held September 22, 2023. The motion was seconded by Mr. Miller and passed unanimously.

## C. <u>Discussion of and Possible Action Regarding Rules</u>

### Final Adoption of Rules

 Rules Concerning Licenses and Registrations for Military Service Members, Military Veterans and Military Spouses (§§283.12 and 297.10) (Items C.1.1.1 and C.1.1.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§283.12 and 297.10 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §§283.12 and 297.10. He explained that the amendments to §283.12 establish procedures for a military service member who is currently licensed in good standing by a jurisdiction with licensing requirements that are substantially similar to Texas's requirements to obtain an interim pharmacist license, in accordance with Senate Bill 422 of the 88th Legislative Session and make grammatical corrections. Additionally, he explained that the amendments to §297.10 establish procedures for a military member who is currently registered in good standing by a jurisdiction with registration requirements that are substantially similar to Texas's requirements to obtain an interim pharmacy technician registration, in accordance with Senate Bill 422 and make grammatical corrections.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by Board Order, the amendments to §§283.12 and 297.10, as presented. The motion was seconded by Ms. Henke and passed unanimously.

 Rules Concerning Temporary Closing (§§291.3 and 291.5) (Items C.1.2.1 and C.1.2.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§291.3 and 291.5 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §§291.3 and

291.5. He explained that the amendments to §291.3 clarify that a pharmacy must notify the board in writing if the pharmacy temporarily closes for the loss of a pharmacist-in-charge and clarify the notification requirements for amending a pharmacy license, and the amendments to §291.5 provide that a pharmacy may temporarily close for the loss of a pharmacist-in-charge if the pharmacy timely notifies the board in writing of the temporary closure.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Ms. Montemayor to approve for adoption, by Board Order, the amendments to §§291.3 and 291.5, as presented. The motion was seconded by Mr. Tisch and passed unanimously.

Rules Concerning Fees (§§291.6, 295.5, and 291.121) (Items C.1.3.1, C.1.3.2, and C.1.3.3)

Mr. Griffith explained that the Board voted to propose the amendments to §§291.6, 295.5, and 291.121 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §§291.6, 295.5, and 291.121. He explained that the amendments to §291.6 specify the application fee for an initial or renewed certificate to provide remote pharmacy services and remove the fee for issuance of a duplicate renewal certificate; the amendments to §295.5 increase pharmacist license fees based on expected expenses; and the amendments to §291.121 clarify how the board provides a license to engage in remote pharmacy services.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Tisch to approve for adoption, by Board Order, the amendments to §§291.6, 295.5, and 291.121, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

Rules Concerning Return of Prescription Drugs (§291.8) (Item C.1.4)

Mr. Griffith explained that the Board voted to propose the amendments to §291.8 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §291.8 and explained that the amendments update the name of a state agency.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Miller to approve for adoption, by Board Order, the amendments to §291.8, as presented. The motion was seconded by Ms. Yoakum and passed unanimously.

 Rules Concerning Community Pharmacy (Class A) Operational Standards (§291.33) (Item C.1.5)

Mr. Griffith explained that the Board voted to propose the amendments to §291.33 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to amendments to §291.33 and explained that the amendments to §291.33 specify prepackaging and labeling requirements for a participating provider to dispense donated prescription drugs under Chapter 442, Health and Safety Code, in accordance with House Bill 4332 of the 88<sup>th</sup> Legislative Session. He also explained that a revised version had been prepared by Board staff addressing the below-listed comments received.

Written comments were received from George Wang, Ph.D., with SIRUM, in support of the amendments and suggesting changes to certain terms and phrases for consistency with statutory language.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Ms. Montemayor to approve for adoption, by Board Order, the amendments to §291.33, as revised. The motion was seconded by Mr. Lewis and passed unanimously.

 Rules Concerning Institutional Pharmacy (Class C) Operational Standards (§291.74) (Item C.1.6)

Mr. Griffith explained that the Board voted to propose the amendments to §291.74 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §291.74 and explained that the amendments re-insert rule text that was inadvertently removed and make grammatical corrections.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Tisch to approve for adoption, by Board Order, the amendments to §291.74, as presented. The motion was seconded by Ms. Montemayor and passed unanimously.

Rules Concerning Satellite Pharmacies (§291.129) (Item C.1.7)

Mr. Griffith explained that the Board voted to propose the amendments to §291.129 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §291.129 and explained that the amendments clarify how the board provides a satellite pharmacy license.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Miller to approve for adoption, by Board Order, the amendments to §291.129, as presented. The motion was seconded by Mr. Tisch and passed unanimously.

 Rules Concerning Continuing Education Requirements (§§295.8 and 295.9) (Items C.1.8.1 and C.1.8.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§295.8 and 295.9 during its August 1, 2023, meeting. The proposed amendments were published in the September 22, 2023, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §§295.8 and 295.9. He explained that the amendments to §295.8 remove continuing education requirements that have expired and the amendments to §295.9 remove a continuing education requirement for which the statutory authority has expired from the conditions for reactivation of an inactive license and make a grammatical correction.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by Board Order, the amendments to §§295.8 and 295.9, as presented. The motion was seconded by Ms. Montemayor and passed unanimously.

#### Proposal of Rules

 Rules Concerning Fee Requirements for Licensure by Examination, Score Transfer and Reciprocity (§283.9) (Item C.2.1)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning fee requirements for licensure by examination, score transfer, and reciprocity. He explained the proposed amendments to §283.9 clarify how the board calculates the fee for failing to timely submit the initial renewal application and license fee for a license to practice pharmacy and correct grammatical errors.

Following discussion, the motion was made by Mr. Tisch to approve for proposal amendments to §283.9, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

 Rules Concerning Licenses and Registrations for Military Service Members, Military Veterans and Military Spouses (§§283.12 and 297.10) (Items C.2.2.1 and C.2.2.2)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning licenses and registrations for military service members, military veterans, and military spouses. He explained the proposed amendments to §283.12 clarify that the requirements for obtaining an interim license for a military service member or military spouse do not affect rights that may be provided under federal law, and the proposed amendments to §297.10 clarify that the requirements for obtaining an interim registration for a military service member or military spouse do not affect rights that may be provided under federal law.

Following discussion, the motion was made by Mr. Miller to approve for proposal amendments to §§283.12 and 297.10, as presented. The motion was seconded by Mr. Tisch and passed unanimously.

Rules Concerning Delivery of Prescription Drugs (§291.12) (Item C.2.3)

Mr. Griffith directed the Board's attention to suggested new rule language concerning delivery of prescription drugs and explained that the Board previously reviewed the new rule language and voted to send the rule back to Board staff for revisions at its August 1, 2023, meeting. Additionally, he explained that the new rule would specify requirements for the delivery of prescription drugs to a patient or patient's agent. He also explained that two options, Option A and Option B, were being presented, and reviewed the two options.

Oral comments were received from Debbie Garza, R.Ph., CEO, Texas Pharmacy Association, partially in support of the proposed rule with suggested changes.

During discussion, the motion was made by Ms. Tijerina to use Option A as the base language for their review to suggest modifications. The motion was seconded by Ms. Henke and passed 8-1-0, with Mr. Guerrero opposed.

Following discussion, the Board directed Board staff to revise the rule language for §291.12 using their line-item recommendations to Option A.

### D. <u>Discussion of and Possible Action Concerning Pilot Projects</u>

 Report on Pilot Project Concerning Residential Delivery of Prescription Drugs by Means of Drone Delivery Service

President Spier directed the Board's attention to a report from Amazon Pharmacy regarding the pilot project concerning residential delivery of prescription drugs by means of drone delivery service.

President Spier recognized the Sean Baird, Senior Corporate Counsel, Amazon Legal, and Ehihimen Okogbo, R.Ph., Pharmacist-in-Charge of Amazon Pharmacy #008, who reviewed the report and answered questions from the Board concerning the pilot project.

# C. <u>Discussion of and Possible Action Regarding Rules, continued</u>

#### Proposal of Rules, continued

 Rules Concerning Institutional Pharmacy (Class C) Operational Standards (§291.74) (Item C.2.4)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning institutional pharmacy (Class C) operational standards. He explained that the proposed amendments to §291.74 specify prepackaging and labeling requirements for a participating provider to dispense donated prescription drugs under Chapter 442, Health and Safety Code, in accordance with House Bill 4332 of the 88<sup>th</sup> Legislative Session.

Following discussion, the motion was made by Mr. Tisch to approve for proposal amendments to §291.74, as presented. The motion was seconded by Ms. Henke and passed unanimously.

 Rules Concerning Pharmacy Responsibility - Out-of-State Practitioner (§315.9) (Item C.2.5)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning pharmacy responsibility with regards to prescriptions issued by out-of-state practitioners. He explained the proposed amendments to §315.9 clarify that the requirements for dispensing a Schedule II controlled substance prescription issued by a practitioner in another state apply to an electronic prescription and remove the effective date from the short title.

Following discussion, the motion was made by Ms. Yoakum to approve for proposal amendments to §315.9, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

#### Rule Review

For Proposal

Mr. Griffith directed the Board's attention to the Board Review Plan for FY2022-FY2025 (Item C.3).

- Chapter 291 Concerning Pharmacies (Community Pharmacy (Class A)) (§§291.31 – 291.36) (Item C.3.1.1)
- Chapter 283 Concerning Licensing Requirements for Pharmacists (§§283.1 – 283.12) (Item C.3.1.2)
- Chapter 315 Concerning Controlled Substances (§§315.1 315.16)
   (Item C.3.1.3)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Mr. Lewis to approve for proposal as presented, the review of Chapter 291 Concerning Pharmacies (Community Pharmacy (Class A)) (§§291.31 – 291.36), Chapter 283 Concerning Licensing Requirements for Pharmacists (§§283.1 – 283.12), and Chapter 315 Concerning Controlled Substances (§§315.1 – 315.16). The motion was seconded by Ms. Montemayor and passed unanimously.

# F. <u>Discussion of and Possible Action Concerning the Following Reports and Discussions</u>

- Professional Recovery Network
  - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for FY2023 (September 1, 2022 – August 31, 2023). (Item F.2.1)
  - President Spier recognized Will Turney, LMSW, PRN Case Manager. Mr. Turney directed the Board's attention to the PRN expense report for FY2023 (September 1, 2022 – August 31, 2023) and reviewed PRN activities for the Board. (Item F.2.2)

President Spier recessed the meeting at 11:43 a.m. President Spier reconvened the meeting at 1:01 p.m.

# E. <u>Discussion of and Possible Action Concerning Reports of Committees/</u> Task Forces

Report on Compounding Rules Advisory Group (Item E.1)

Mr. Miller thanked the members of the sterile and non-sterile subcommittees for their participation in the Compounding Rules Advisory Group. He reviewed some discussion topics from the sterile subcommittee meetings and reported that the next meeting of the sterile subcommittee would be held on January 23, 2024. Additionally, he reported that the non-sterile subcommittee had concluded their recommendations and reviewed some discussion topics from the non-sterile subcommittee meetings.

Ms. Holloway directed the Board's attention to a chart prepared by Board staff indicating the changes recommended by the non-sterile subcommittee to §291.131 in consideration of USP 795 revisions.

Following discussion, a motion was made by Ms. Yoakum to direct Board staff to prepare rule language for §291.131 based on the non-sterile subcommittee's recommendations. The motion was seconded by Mr. Guerrero and passed unanimously.

 Report on Prescription Monitoring Program (PMP) Advisory Committee (Item E.2)

Ms. Holloway reported that the next meeting of the PMP Advisory Committee meeting would be held on December 14, 2023. Ms. Holloway also reported that most of the PMP Advisory Committee members for the next three-year term had been appointed, but that nominations had not been received for the surgical or psychiatric physician members.

 Report on Interagency Prescription Monitoring Program Work Group (Item E.3)

Ms. Holloway reported that the Interagency Prescription Monitoring Program Workgroup Meeting was held on August 21, 2023, and included discussion concerning the recent legislative session and funding for PMP.

# F. <u>Discussion of and Possible Action Concerning the Following Reports and</u> Discussions, continued

- Financial Report
  - Review of FY2023 Third Quarter Expenditures (Item F.1.1)

Mr. Leal reviewed the expenditures for FY2023 (September 1, 2022 – August 31, 2023) for the Board.

Review of Board Member Travel Budget (Item F.1.2)

Mr. Leal reviewed the FY2023 Board Member Travel Budget (September 1, 2022 – August 31, 2023).

 Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item F.1.3)

Mr. Leal reviewed the list of updated contracts for goods and services for the fourth quarter of FY2023 (June 1, 2023 – August 31, 2023) for the Board. He explained that the updates include extensions to the terms of existing contracts.

Discussion Concerning FY2025-2029 Strategic Plan (Item F.3)

President Spier directed the Board's attention to the FY2025-FY2029 Strategic Plan Questionnaire and Timeline and reviewed the questionnaire responses.

Report on Prescription Monitoring Program (Item F.4)

Ms. Holloway reviewed the Prescription Monitoring Program (PMP) data for the fourth quarter of FY2023 (June 1, 2023 – August 31, 2023). She also reported on the successful rollout of integration and Narxcare, the deployment of advanced analytics, and the progress of PMP staffing.

 Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item F.5)

Ms. Holloway provided an update concerning the appeal status of the *Garrett* lawsuit that sought to invalidate the restriction that licensed Texas physicians cannot dispense prescriptions to patients at their offices without a pharmacy license. She explained that the plaintiff's petition for review with the Texas Supreme Court was denied on September 29, 2023.

Ms. Holloway explained that there have been no updates since the last meeting concerning the lawsuit filed by Lightcare Rx, LLC (Texas Pharmacy License #32609) and the pharmacist-in-charge, Leila Elahianboroujeni (Pharmacist License #64241), in the Travis County District Court, appealing the entry of the Board Orders entered in May 2022.

> Discussion Concerning Issuance of Select Pharmacist Licenses in July 2023 (Item F.6)

Ms. Anderson reviewed the pharmacist licensing process. She provided information concerning the issuance of select pharmacist licenses in July 2023, which were incorrectly issued due to duplicate exam results being uploaded. She explained that the matter was quickly resolved, and measures have been put in place to prevent recurrence.

# G. Consideration of and Possible Action Concerning Enforcement Reports

 Report on Complaints Closed and Dismissed During the Previous Quarter (Item G.1)

Ms. Hotchkiss reported on complaints dismissed and closed during FY2023 (September 1, 2022 – August 31, 2023). The report also included a comparison of complaints closed with disciplinary orders to those closed without disciplinary orders and a comparison of quarterly averages for FY2023 to the quarterly averages for FY2022, as well as percentage change from FY2022 to FY2023.

Report on Status of Active/Pending Complaints (Item G.2)

Ms. Hotchkiss reviewed the *Report on Status of Active/Pending Complaints* for the Board.

## H. <u>Disciplinary Orders</u>

- Report on Agreed Board Orders Entered by Board President or Executive Director and Board Orders Entered by Board Panel or Executive Director (Item H.1)
  - The Board reviewed 18 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Board President on behalf of the Board, in accordance with the Board's directives, during the period from August 15, 2023, through October 17, 2023.
  - The Board reviewed 8 Agreed Board Orders concerning pharmacies and pharmacists that had been entered by the Board President on behalf of the Board, in accordance with the Board's directives, during the period from August 15, 2023, through October 5, 2023.
  - The Board reviewed 2 Agreed Board Orders concerning pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, on October 31, 2023.

- The Board reviewed 3 Board Orders concerning pharmacies that had been entered by a Board Panel on behalf of the Board, in accordance with the Board's directives, during the period from September 29, 2023, through October 18, 2023.
- The Board reviewed 1 Board Order concerning a pharmacy that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, on November 3, 2023.
- Discussion of and Action on Proposed Agreed Board Orders, Proposed
   Default Board Orders, and Proposed Remedial Plans (Items H.2 and H.3)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 14 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;
- 7 proposed Default Board Orders concerning pharmacy technicians and pharmacy technician trainees who did not appear for an Informal Conference;
- 20 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 39 proposed Agreed Board Orders concerning pharmacies, pharmacists, and interns who appeared for an Informal Conference;
- 2 proposed Default Board Orders concerning pharmacists who did not appear for an Informal Conference;
- 1 proposed Default Board Orders concerning a pharmacist (Following a State Office of Administrative Hearing);
- 2 proposed Confidential Agreed Board Orders concerning pharmacists who appeared for an Informal Conference;
- 11 proposed Remedial Plans concerning pharmacists (Alternative Resolutions); and
- 3 proposed Remedial Plans concerning pharmacists who attended an Informal Conference.

Ms. Henke made a motion that the Board go into Executive Session to consult with legal counsel under the authority of the Texas Government Code §551.071. The motion was seconded by Mr. Lewis and passed unanimously.

President Spier declared the Board in Executive Session at 1:38 p.m.

At 1:49 p.m., President Spier announced that the Board would resume the meeting in Open Session and that no action was taken, and no decisions were made during Executive Session.

The motion was made by Mr. Guerrero to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Mr. Lewis, and the motion passed as follows:

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
1	Christopher J. Gerold	Т	ABO	2023-02982	7-0-2	Guerrero, Tijerina
2	Tangelia Monique Broussard	Т	ABO	2023-04299	7-0-2	Lewis, Miller
3	Angelica Gordon	Т	ABO	2023-04026	7-0-2	Lewis, Miller
4	Venus Lakisha Ponds	Т	ABO	2023-03068	7-0-2	Lewis, Miller
5	Jamie Lynn Cardenas	Т	ABO	2023-05270	7-0-2	Miller, Tijerina
6	Andrew Castaneda	Т	ABO	2023-05168	7-0-2	Miller, Tijerina
7	Viridiana Anessy Hernandez	Т	ABO	2023-05878	7-0-2	Miller, Tijerina
8	Allysa Marie Leihgeber	Т	ABO	2022-07617	7-0-2	Miller, Tijerina
9	Jalisa Elizabeth Morris	Т	ABO	2023-04414	7-0-2	Miller, Tijerina
10	Victor Chima Ogwo	Т	ABO	2022-07367	7-0-2	Miller, Tijerina
11	Joshua Tyler Olsen	Т	ABO	2023-05174	7-0-2	Miller, Tijerina
12	Alonzo Pena	Т	ABO	2023-04773	7-0-2	Miller, Tijerina
13	Issa Yagi	Т	ABO	2023-04378	7-0-2	Miller, Tijerina
14	Star Francis Young	Т	ABO	2023-05213	7-0-2	Miller, Tijerina
15	Fatima Brown	Т	DBO	2023-05139	7-0-2	Miller, Tijerina
16	Ariel Toylean Johnson	Т	DBO	2023-04107	7-0-2	Miller, Tijerina
17	Brieana Deshawn Risper	Т	DBO	2023-05052	7-0-2	Miller, Tijerina
18	Christine N. Jason	Т	DBO	2023-06265	7-0-2	Miller, Montemayor
19	Tonnell Lucatricia Jefferson	Т	DBO	2023-04927	7-0-2	Miller, Montemayor
20	Aaron Michael Ramirez	Т	DBO	2023-06064	7-0-2	Miller, Montemayor
21	Francisco Tran	Т	DBO	2023-06541	7-0-2	Miller, Montemayor
22	Costco Pharmacy #1152	Р	ABO	2023-02778	9-0-0	-
23	CVS/pharmacy #928	Р	ABO	2023-01530	8-0-1	Tijerina

<sup>\*</sup>Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
24	CVS/pharmacy #6955	Р	ABO	2022-04293	8-0-1	Tijerina
25	CVS/pharmacy #10412	Р	ABO	2023-02105	8-0-1	Tijerina
26	CVS/pharmacy #10886	Р	ABO	2022-05804	8-0-1	Tijerina
27	Genoa Healthcare LLC	Р	ABO	2023-01796	9-0-0	-
28	Healthwise Rx	Р	ABO	2023-01379	9-0-0	-
29	IsoRx San Angelo	Р	ABO	2023-03232	9-0-0	-
30	J. Brooks Joe Jr.	R	ABO	2023-03197	9-0-0	-
31	Medsaver Pharmacy	Р	ABO	2023-01709	9-0-0	-
32	Sovong Mey	R	ABO	2023-04199	9-0-0	-
33	miRx Pharmacy	Р	ABO	2023-01180	9-0-0	-
34	Next Level Pharmacy	Р	ABO	2023-00045	9-0-0	-
35	Pharm House Drug – Needville LLC	Р	ABO	2022-07809	9-0-0	-
36	Quick Care Pharmacy	Р	ABO	2023-03626	9-0-0	-
37	Walgreens #09647	Р	ABO	2022-06397	8-0-1	Fernandez
38	Walgreens #6510	Р	ABO	2022-06416	8-0-1	Fernandez
39	Walgreens #7251	Р	ABO	2023-01785	8-0-1	Fernandez
40	Walter R. Wilson	R	ABO	2023-04324	9-0-0	-
41	WiRx Pharmacy	Р	ABO	2023-03241	9-0-0	-
42	R & Y Community Pharmacy, LLC	Р	ABO	2022-06660	7-0-2	Henke, Lewis
43	Riel Ndukaego Emordi	R	ABO	2022-04054	7-0-2	Henke, Lewis
44	Coldspring Pharmacy	Р	ABO	2022-05664	7-0-2	Henke, Montemayor
45	Live Oak Pharmacy	Р	ABO	2022-01968	7-0-2	Henke, Montemayor
46	MedRx Pharmacy	Р	ABO	2022-00032	7-0-2	Henke Montemayor
47	CentRx Pharmacy at Texoma	Р	ABO	2022-06422	8-0-1	Lewis
48	CVS/pharmacy #10909	Р	ABO	2022-07056	7-0-2	Lewis, Tijerina
49	Farmacia La Unica	Р	ABO	2023-01175	7-0-2	Guerrero, Tijerina
50	Mace Care Pharmacy LLC	Р	ABO	2023-03236	7-0-2	Guerrero, Tijerina
51	Omar Yahya Moohammed	R	ABO	2023-01581	7-0-2	Guerrero, Tijerina
52	Walgreens #13786	Р	ABO	2022-07705	6-0-3	Fernandez, Guerrero, Tijerina
53	Maria Nu Ton	R	ABO	2022-07529	7-0-2	Guerrero, Tijerina
54	CVS/pharmacy #6825	Р	ABO	2022-07286	6-0-3	Lewis, Miller, Tijerina
55	CVS/pharmacy #10540	Р	ABO	2022-06600	6-0-3	Lewis, Miller, Tijerina

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
56	CVS/pharmacy #16021	Р	ABO	2023-01315	6-0-3	Lewis, Miller, Tijerina
57	John Unamalu Odumah	R	ABO	2023-02511	7-0-2	Lewis, Miller
58	Linda Van Ratliff Davis	R	ABO	2023-00702	7-0-2	Lewis, Miller
59	Nermin Awad El Hadik	R	ABO	2023-03414	7-0-2	Lewis, Miller
60	FUC PHS Pharmacy	Р	ABO	2023-02633	7-0-2	Lewis, Miller
61	Patrick Tchoumi	R	ABO	2023-03713	7-0-2	Lewis, Miller
62	Jerry Wayne Haynes	R	ABO	2023-02975	7-0-2	Lewis, Miller
63	Maxcare Family Pharmacy	Р	ABO	2022-06277	7-0-2	Lewis, Miller
64	Saju K. Asthappan	R	ABO	2023-02494	7-0-2	Lewis, Miller
65	Lateef Abioye Odeyemi	R	ABO	2023-03097	7-0-2	Lewis, Miller
66	Praxis Rx Pharmacy	Р	ABO	2023-00586	7-0-2	Lewis, Miller
67	Raul Demetrio Rendon	R	ABO	2023-04527	7-0-2	Lewis, Miller
68	Shondon Lashon Stoker	ı	ABO	2023-01736	7-0-2	Lewis, Miller
69	Texas Star Pharmacy	Р	ABO	2022-03129	7-0-2	Lewis, Miller
70	Raman Bhaumik	R	ABO	2022-06990	7-0-2	Lewis, Miller
71	Walgreens #6661	Р	ABO	2022-07678	6-0-3	Fernandez, Lewis, Miller
72	Gregory Scott McHugh	R	ABO	2023-01873	6-0-3	Fernandez, Lewis, Miller
73	George Antwi Ampofo	R	ABO	2023-01960	7-0-2	Miller, Tijerina
74	Cure Rx LLC	Р	ABO	2022-07060	7-0-2	Miller, Tijerina
75	CVS/pharmacy #3197	Р	ABO	2023-02140	7-0-2	Miller, Tijerina
76	Linda Johansen	R	ABO	2022-05614	7-0-2	Miller, Tijerina
77	New Solutions Functional Wellness Pharmacy	Р	АВО	2023-03258	5-0-4	Henke, Miller, Tijerina, Yoakum
78	Mikala Jill Conatser	R	АВО	2023-04352	5-0-4	Henke, Miller, Tijerina, Yoakum
79	Walgreens #04459	Р	ABO	2023-02012	6-0-3	Fernandez, Miller, Tijerina
80	Jane Cupit-Benzick	R	ABO	2023-02176	7-0-2	Miller, Montemayor
81	Keith Marcell Hudson	R	DBO	2023-04074	7-0-2	Miller, Tijerina
82	Anthony Obute	R	DBO	2023-04176	7-0-2	Miller, Tijerina
83	Janelle Lateesh Harris	R	DBO	2022-03766	8-0-1	Lewis
84	Confidential	R	ABO	2023-02488	7-0-2	Miller, Tijerina
85	Confidential	R	ABO	2023-04960	7-0-2	Miller, Montemayor
86	Aya Al-Ezzi	R	RP	2023-02572	9-0-0	-
87	Julia Diana Busse	R	RP	2023-03190	9-0-0	-
88	Chih Lin Chou	R	RP	2023-03685	9-0-0	-
89	Tony Diep	R	RP	2023-04699	9-0-0	-
90	Louis Dinh	R	RP	2023-04219	9-0-0	-

<sup>\*</sup>Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
91	Jeffrey Alan Neale	R	RP	2023-04631	9-0-0	-
92	Dongbao Hua Nguyen	R	RP	2023-04768	9-0-0	-
93	Tracey Lan Nguyen	R	RP	2023-00470	9-0-0	-
94	Patricia Chidinma Otuonye	R	RP	2023-05330	9-0-0	-
95	Alex Hyuk Park	R	RP	2023-03830	9-0-0	-
96	Julie Vu	R	RP	2023-03950	9-0-0	-
97	Dennis Wayne Helbert	R	RP	2022-04805	7-0-2	Henke, Montemayor
98	Michael Marvin O'Day	R	RP	2022-06929	7-0-2	Guerrero, Tijerina
99	Jovita Nwabuaku Achife	R	RP	2022-07844	7-0-2	Lewis, Miller

<sup>\*</sup>Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)
\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

## I. <u>Miscellaneous</u>

 Items to be Placed on Agenda for February 6, 2024, Board Meeting (Item I.1)

President Spier requested Board members to submit any additional items for the February 6, 2024, Board meeting to staff.

Recap of Agency Activities (Item I.2)

Ms. Holloway reviewed her recent attendance at MALTAGON.

President Spier reviewed her recent attendance at the NABP District 6, 7, and 8 Meeting, which was also attended by Mr. Miller and Mr. Lewis.

Mr. Briggs reviewed his recent attendance at the American Society for Pharmacy Law conference, which was also attended by Ms. Holloway and Mr. Griffith.

Discussion of and Possible Action on Upcoming Meetings (Item I.3)

President Spier reviewed upcoming meetings and conferences.

Ms. Henke made a motion to adjourn the meeting. The motion was seconded by Mr. Lewis and passed unanimously.

President Spier adjourned the meeting at 2:00 p.m.

APPROVED:

Julie Spier, R.Ph. President

Daniel Carroll, Pharm.D., R.Ph. Executive Director/Secretary

February 6, 2024